AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer

MT Newswires Live05-13

AngioDynamics (ANGO) shares were up close to 3% in Wednesday trading after it said two-year results from the PRESERVE pivotal trial demonstrated "durable oncologic control and a sustained safety profile" for its NanoKnife System for prostate tissue ablation in patients with intermediate-risk prostate cancer.

The study is evaluating focal irreversible electroporation using the NanoKnife System in 121 patients with Gleason Grade Group 2-3 intermediate-risk prostate cancer.

The company's NanoKnife System, which uses irreversible electroporation, is intended to reduce quality of life complications, according to a study archived by the National Institutes of Health's National Library of Medicine.

Shares of AngioDynamics were up close to 3% in Wednesday trading.

Price: 10.94, Change: +0.04, Percent Change: +0.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635738453?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635738453","market":"sh","top_or_hot":-1,"title":"AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer","media":"MT Newswires Live","content":"<html><body><p> AngioDynamics (ANGO) shares were up close to 3% in Wednesday trading after it said two-year results from the PRESERVE pivotal trial demonstrated \"durable oncologic control and a sustained safety profile\" for its NanoKnife System for prostate tissue ablation in patients with intermediate-risk prostate cancer.</p><p>The study is evaluating focal irreversible electroporation using the NanoKnife System in 121 patients with Gleason Grade Group 2-3 intermediate-risk prostate cancer.</p><p>The company's NanoKnife System, which uses irreversible electroporation, is intended to reduce quality of life complications, according to a study archived by the National Institutes of Health's National Library of Medicine.</p><p>Shares of AngioDynamics were up close to 3% in Wednesday trading.</p><p>Price: 10.94, Change: +0.04, Percent Change: +0.37</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-13 21:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AngioDynamics (ANGO) shares were up close to 3% in Wednesday trading after it said two-year results from the PRESERVE pivotal trial demonstrated \"durable oncologic control and a sustained safety profile\" for its NanoKnife System for prostate tissue ablation in patients with intermediate-risk prostate cancer.</p><p>The study is evaluating focal irreversible electroporation using the NanoKnife System in 121 patients with Gleason Grade Group 2-3 intermediate-risk prostate cancer.</p><p>The company's NanoKnife System, which uses irreversible electroporation, is intended to reduce quality of life complications, according to a study archived by the National Institutes of Health's National Library of Medicine.</p><p>Shares of AngioDynamics were up close to 3% in Wednesday trading.</p><p>Price: 10.94, Change: +0.04, Percent Change: +0.37</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635738453","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635738453","pubTimestamp":1778680720,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AngioDynamics  shares were up close to 3% in Wednesday trading after it said two-year results from the PRESERVE pivotal trial demonstrated \"durable oncologic control and a sustained safety profile\" for its NanoKnife System for prostate tissue ablation in patients with intermediate-risk prostate cancer.The study is evaluating focal irreversible electroporation using the NanoKnife System in 121 patients with Gleason Grade Group 2-3 intermediate-risk prostate cancer.The company's NanoKnife System, which uses irreversible electroporation, is intended to reduce quality of life complications, according to a study archived by the National Institutes of Health's National Library of Medicine.Shares of AngioDynamics were up close to 3% in Wednesday trading.Price: 10.94, Change: +0.04, Percent Change: +0.37","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ANGO":"Angiodynamics"},"translate_title":"血管动力学报告纳米刀治疗中等风险前列腺癌研究中的“持久肿瘤控制”","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":1.5},"content_text":"AngioDynamics (ANGO) shares were up close to 3% in Wednesday trading after it said two-year results from the PRESERVE pivotal trial demonstrated \"durable oncologic control and a sustained safety profile\" for its NanoKnife System for prostate tissue ablation in patients with intermediate-risk prostate cancer.The study is evaluating focal irreversible electroporation using the NanoKnife System in 121 patients with Gleason Grade Group 2-3 intermediate-risk prostate cancer.The company's NanoKnife System, which uses irreversible electroporation, is intended to reduce quality of life complications, according to a study archived by the National Institutes of Health's National Library of Medicine.Shares of AngioDynamics were up close to 3% in Wednesday trading.Price: 10.94, Change: +0.04, Percent Change: +0.37","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635738453","isCrawlerRequest":true}